MX2013003306A - Sistema y composiciones mejorados para la administracion transbucal de farmacos. - Google Patents
Sistema y composiciones mejorados para la administracion transbucal de farmacos.Info
- Publication number
- MX2013003306A MX2013003306A MX2013003306A MX2013003306A MX2013003306A MX 2013003306 A MX2013003306 A MX 2013003306A MX 2013003306 A MX2013003306 A MX 2013003306A MX 2013003306 A MX2013003306 A MX 2013003306A MX 2013003306 A MX2013003306 A MX 2013003306A
- Authority
- MX
- Mexico
- Prior art keywords
- delivery system
- enhanced
- compositions
- drug delivery
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Addiction (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulga un sistema de administración bucal adecuado para la administración de un agente terapéutico a la cavidad oral de un paciente. El sistema de administración comprende una matriz para contener y liberar el agente terapéutico en la cavidad oral y un alquilo amino acetato N, N-disustituido en dicha matriz. Un sistema de administración particularmente preferido comprende una matriz que contiene una cantidad efectiva de agente terapéutico junto con un alquilo amino acetato N, N-disustituido, tal como sal de dodecilo 2-(N, N-dimetilamino)propionato.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38600110P | 2010-09-24 | 2010-09-24 | |
| PCT/US2011/001645 WO2012039775A1 (en) | 2010-09-24 | 2011-09-23 | Enhanced transbuccal drug delivery system and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013003306A true MX2013003306A (es) | 2013-07-29 |
Family
ID=45874093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013003306A MX2013003306A (es) | 2010-09-24 | 2011-09-23 | Sistema y composiciones mejorados para la administracion transbucal de farmacos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130178463A1 (es) |
| EP (1) | EP2619175A1 (es) |
| JP (1) | JP2013537906A (es) |
| KR (1) | KR20140016239A (es) |
| CN (1) | CN103237785A (es) |
| AU (1) | AU2011306050A1 (es) |
| BR (1) | BR112013006632A2 (es) |
| CA (1) | CA2811962A1 (es) |
| CR (1) | CR20130174A (es) |
| IL (1) | IL225485A0 (es) |
| MX (1) | MX2013003306A (es) |
| PH (1) | PH12013500552A1 (es) |
| RU (1) | RU2013112765A (es) |
| SG (1) | SG188612A1 (es) |
| WO (1) | WO2012039775A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200514579A (en) | 2003-07-24 | 2005-05-01 | Smithkline Beecham Corp | Orally dissolving films |
| MX2012012824A (es) * | 2010-05-04 | 2013-07-03 | Nexmed Holdings Inc | Composiciones de productos terapeuticos de moleculas pequeñas. |
| JP6538063B2 (ja) * | 2013-11-05 | 2019-07-03 | シンアジャル コーポレイション | 口を介する連続的薬物送達のためのデバイスおよび方法 |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| US10172833B2 (en) | 2015-08-11 | 2019-01-08 | Insys Development Company, Inc. | Sublingual ondansetron spray |
| SE1750680A1 (en) * | 2017-05-30 | 2018-12-01 | Peptonic Medical Ab | Composition for treating or preventing climacteric disorders |
| CN117205183A (zh) * | 2023-09-28 | 2023-12-12 | 深圳华宝协同创新技术研究院有限公司 | 一种尼古丁口腔膜剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082866A (en) * | 1988-06-01 | 1992-01-21 | Odontex, Inc. | Biodegradable absorption enhancers |
| US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| US6118020A (en) * | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| US7105571B2 (en) * | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US20070269379A1 (en) * | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
-
2011
- 2011-09-23 KR KR1020137010300A patent/KR20140016239A/ko not_active Withdrawn
- 2011-09-23 JP JP2013530135A patent/JP2013537906A/ja not_active Withdrawn
- 2011-09-23 MX MX2013003306A patent/MX2013003306A/es not_active Application Discontinuation
- 2011-09-23 BR BR112013006632A patent/BR112013006632A2/pt not_active IP Right Cessation
- 2011-09-23 PH PH1/2013/500552A patent/PH12013500552A1/en unknown
- 2011-09-23 CN CN2011800565798A patent/CN103237785A/zh active Pending
- 2011-09-23 CA CA2811962A patent/CA2811962A1/en not_active Abandoned
- 2011-09-23 US US13/825,823 patent/US20130178463A1/en not_active Abandoned
- 2011-09-23 AU AU2011306050A patent/AU2011306050A1/en not_active Abandoned
- 2011-09-23 WO PCT/US2011/001645 patent/WO2012039775A1/en not_active Ceased
- 2011-09-23 RU RU2013112765/15A patent/RU2013112765A/ru unknown
- 2011-09-23 EP EP11827100.6A patent/EP2619175A1/en not_active Withdrawn
- 2011-09-23 SG SG2013020466A patent/SG188612A1/en unknown
-
2013
- 2013-03-24 IL IL225485A patent/IL225485A0/en unknown
- 2013-04-22 CR CR20130174A patent/CR20130174A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011306050A1 (en) | 2013-04-11 |
| SG188612A1 (en) | 2013-04-30 |
| US20130178463A1 (en) | 2013-07-11 |
| KR20140016239A (ko) | 2014-02-07 |
| IL225485A0 (en) | 2013-06-27 |
| CN103237785A (zh) | 2013-08-07 |
| JP2013537906A (ja) | 2013-10-07 |
| CA2811962A1 (en) | 2012-03-29 |
| CR20130174A (es) | 2013-05-31 |
| RU2013112765A (ru) | 2014-10-27 |
| BR112013006632A2 (pt) | 2017-07-18 |
| PH12013500552A1 (en) | 2013-05-06 |
| EP2619175A1 (en) | 2013-07-31 |
| WO2012039775A1 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500552A1 (en) | Enhanced transbuccal drug delivery system and compositions | |
| EP2105129A3 (en) | Encapsulated Vaccines for the Oral Vaccination and Boostering of Fish and Other Animals | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| MX369121B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
| PH12012502161A1 (en) | Pharmaceutical formulations comprising pioglitazone and linagliptin | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| IL216741A (en) | History of imidazolidine-2-van 1,3-imaging modalities as 17-cyp inhibitors, pharmaceutical preparations containing them, and their use in the preparation of drugs for the treatment of diseases | |
| MX346879B (es) | Formulaciones de ketorolaco listas para su uso. | |
| CY1116698T1 (el) | Συνθεση περιεχοντας υπερ-μικρονοποιημενο παλμιτοϋλ-αιθανολαμιδιο | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| PH12017501688A1 (en) | Intranasal benzodiazepine pharmaceutical compositions | |
| BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| MX2011011829A (es) | Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico. | |
| TN2010000135A1 (en) | Galenical formulations of organic compounds | |
| MX2012008413A (es) | Composicion novedosa de retigabina. | |
| MX347101B (es) | Forma de dosis de disolucion rapida de vacuna oral que usa almidon. | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| IN2014CN04119A (es) | ||
| MX2011009846A (es) | Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno. | |
| MX336037B (es) | Composicion y metodo de peptido terapeutico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |